Nippon India Pharma Fund - Dividend - Regular Plan

  • Previous Nav

  • Net Change on 19-01-2021

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Dividend | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund-Dividend-Dividend 1.02 9.74 59.38 19.90 12.64 21.24
S&P BSE Health Care 1.76 10.69 55.53 13.69 7.00 15.06
S&P BSE Health Care - TRI 1.76 10.75 56.65 14.47 7.69 14.97
S&P BSE SENSEX - TRI 5.20 22.41 19.22 12.96 16.52 13.54

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Dividend-Dividend Jun 05, 2004 59.38 19.90 12.64 2.02 4,383.33
UTI Healthcare Fund - Regular Plan - Income Option Aug 25, 1999 58.85 15.91 9.91 2.80 649.26
Tata India Pharma & Healthcare Fund-Regular Plan-Dividend Dec 28, 2015 55.97 18.60 9.23 2.63 419.33
Tata India Pharma & Healthcare Fund-Regular Plan-Dividend Payout Dec 28, 2015 55.97 18.60 9.23 2.63 419.33

Fund Holdings as on 31-December-2020

  • Sun Pharmaceutical Industries Limited

  • Aurobindo Pharma Limited

  • Cipla Limited

  • Divi's Laboratories Limited

  • Lupin Limited

  • Dr. Reddy's Laboratories Limited

  • Cadila Healthcare Limited

  • Fortis Healthcare Limited

  • Gland Pharma Limited

  • Thyrocare Technologies Limited

  • Narayana Hrudayalaya Limited

  • Apollo Hospitals Enterprise Limited

  • Sanofi India Limited

  • Abbott India Limited

  • Triparty Repo

  • Indoco Remedies Limited

  • Biocon Limited

  • Shilpa Medicare Limited

  • Torrent Pharmaceuticals Limited

  • Syngene International Limited

  • Healthcare Global Enterprises Limited

  • Cash Margin - Derivatives

  • Alkem Laboratories Limited

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

View More

Fund Manager

Most Recent Dividend

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • 14/01/2013

  • 16/03/2012

  • 28/02/2011

  • 31/08/2009

  • 24/03/2008

  • 22/02/2007

  • 19/12/2005

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹4,383.33 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care as primary index and S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended up ₹1.35(1.7%)yesterday to ₹80.6805.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan and Kinjal Desai.

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097